Addison's disease market seen reaching $3.53 billion by 2030

The Business Research Company projects the global Addison's disease market will grow from $2.46 billion in 2026 to $3.53 billion by 2030. The report points to rising autoimmune disease rates, broader diagnostic access and newer treatment approaches as key growth drivers.

Why it matters: - The Addison's disease market is expanding as diagnosis, monitoring and hormone replacement care become more accessible. - The forecast points to more demand for long-term treatment and testing as autoimmune disease prevalence rises. - The market's growth reflects a wider push toward earlier diagnosis and more personalized care for rare endocrine disorders.

What happened: - The Business Research Company released its Global Addison's Disease Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will rise from $2.24 billion in 2025 to $2.46 billion in 2026. - The report projects the market will reach $3.53 billion by 2030. - The company said the market is growing at a 9.7% CAGR in the historical period and is expected to grow at a 9.4% CAGR through 2030. - A free sample of the report is available here. - The full report is available here.

The details: - Addison's disease is a rare disorder caused by insufficient cortisol and aldosterone production after damage to the adrenal glands, often from an autoimmune response. - Common symptoms include fatigue, muscle weakness, weight loss, low mood and changes in skin pigmentation. - Lifelong hormone replacement therapy is required to prevent serious complications, including adrenal crisis. - Historical growth has been linked to limited disease awareness, constrained diagnostic access, reliance on traditional corticosteroid treatments, higher autoimmune disease prevalence and expansion of hospital and clinical facilities. - Future growth is tied to targeted adrenal insufficiency therapies, broader use of patient monitoring systems, growth in diagnostic laboratory networks, more research in autoimmune and adrenal diseases, and personalized medicine initiatives. - Key trends include greater use of hormone replacement therapies, expanded diagnostic testing, rising prescriptions of hydrocortisone and fludrocortisone, more autoimmune disease research and a stronger focus on early diagnosis and patient monitoring. - The report says autoimmune disease prevalence is a major driver because these conditions can coexist and raise the likelihood of Addison's disease cases. - In March 2025, the Sjögren's Foundation said autoimmune illnesses affect more than 50 million Americans, or 8% of the U.S. population. - In 2025, North America held the largest share of the Addison's disease market. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The forecast suggests rare disease markets are increasingly shaped by diagnostics and care delivery, not just drug demand. - North America's current lead and Asia-Pacific's faster growth point to a maturing market in established healthcare systems and new upside in expanding ones. - The report's emphasis on monitoring, laboratory networks and personalized medicine signals that infrastructure is becoming as important as treatment innovation.

What's next: - The market's next phase will likely depend on whether targeted therapies and better screening move from forecast to routine practice. - Expansion in autoimmune research and diagnostic networks could sharpen early detection and lift treatment demand further. - Regional growth patterns will be a key watch item as Asia-Pacific narrows the gap with North America.